View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
In association with SHL Medical

Redefining the Autoinjector Platform


The injectable drug delivery industry as a whole has been moving towards developing platform device technologies, which are defined by a preset design and a cohesive architecture that can be shared by products within the same family. Platform technologies are designed to support faster development and reduced costs, but the conventional scope is now posing new challenges to device developers as well as their pharmaceutical partners. This is especially true when distinct industrial designs or specific primary container types become necessary to accommodate new generations of medications and different patients’ needs.

Free Whitepaper
img

A systematic review of Molly®’s integrated and flexible device design and development model

Self-administered injectable medicines are a crucial part of home-based disease management and treatment. As the world accelerates towards new digital horizons and the promise of Healthcare 4.0, fresh perspectives on how to optimise device design and manufacturing are needed. SHL Medical’s Molly® family of autoinjector devices harnesses the power of modularity at all stages of the product life cycle to deliver a truly customisable and sustainable solution to the increasing need for self-administered parenteral medicaments. Learn more about SHL’s innovative approach to combination products built upon scalable platform-technologies. Download now to discover how their approach promises to play an integral part in the emerging paradigm shift.
by SHL Medical
Enter your details here to receive your free Whitepaper.

What device companies need are device designs and production processes that can offer flexibility beyond the traditional platform technology – a modular platform technology.

The modular platform technology

The concept of modularity originates from the general attempt to understand and operationalize complex systems. In a modular platform, the product is divided into modules that can be exchanged with other elements of different sizes or functionality to create variants.1 Asset flexibility, cost of goods, and investment deferment are just some of the key drivers behind modular systems.2 When done correctly, modularity supports standardization, repeatability, as well as customization.

In the autoinjector industry, modularity refers to a solution that leverages the benefits of a platform device technology while still allowing various customizations in the device design and development models. SHL Medical’s Molly® family of autoinjectors is indicative of how modularity built upon an established platform can enable flexibility, scalability, and timeliness.

Built upon a modular platform technology, the 1.0mL and 2.25mL Molly autoinjectors enable an appreciable level of flexibility for customization in their industrial designs, such as customizing the color of the cap, plunger rod, and needle cover, or the shape of the cap and body to create an autoinjector with a bespoke design. These customizations, whether for branding and market differentiation or for patient usability and distinguishability, are implemented while maintaining Molly’s rotator-based mechanism – the core technology supporting the many Molly autoinjectors deployed to patients around the world.3

SHL Medical’s Molly autoinjector is built upon a modular platform technology designed to support various levels of customization of the device’s design and development models

Molly’s modularity further extends to various layers of the device development process, including component assembly and final device testing. The mature infrastructure of SHL’s in-house design and development ecosystem makes it possible to share manufacturing assets across multiple Molly device projects, resulting in the simplification of the development process and the optimization of project timelines.

Supporting patient-centric healthcare

The autoinjector market will become increasingly patient-focused, creating an imperative for flexible and modular tools and technologies that help bring innovative drugs to patients. The flexibility offered by Molly’s modular platform technology has been successfully embodied in multiple commercial launches with various levels of design customization, treating a myriad of disease areas that cover 85% of the most common afflictions requiring injected medicines.4

While these successes validate the stratification of Molly’s offerings in the market, Molly’s true value lies in its flexible design and development model that allows for future extension – including production scalability and lifecycle management − in response to industrial advancements, such as in data science, connectivity, and sustainability.

For more information, visit the Molly website, or download the Molly White Paper.

References:

  1. Zha, Xuan F., and Ram D. Sriram. “Platform-Based Product Design and Development: A Knowledge-Intensive Support Approach.” Knowledge-Based Systems, vol. 19, no. 7, pp. 524–543, 2006.
  2. Hernandez R, “Modular Manufacturing Platforms for Biologics”. BioPharm International, 28 (5), 2015.
  3. SHL Medical. Molly webpage. 2021.
  4. Pharmaceutical Technology “How autoinjector devices breathe new life into injectable medicines”. 2021.

Free Whitepaper
img

A systematic review of Molly®’s integrated and flexible device design and development model

Self-administered injectable medicines are a crucial part of home-based disease management and treatment. As the world accelerates towards new digital horizons and the promise of Healthcare 4.0, fresh perspectives on how to optimise device design and manufacturing are needed. SHL Medical’s Molly® family of autoinjector devices harnesses the power of modularity at all stages of the product life cycle to deliver a truly customisable and sustainable solution to the increasing need for self-administered parenteral medicaments. Learn more about SHL’s innovative approach to combination products built upon scalable platform-technologies. Download now to discover how their approach promises to play an integral part in the emerging paradigm shift.
by SHL Medical
Enter your details here to receive your free Whitepaper.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU